China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma's deal with the US pharmaceutical giant underscores China's growing role in global biotech licensing US ...

Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Zealand Pharma seeks to challenge GLP‑1 dominance with obesity drug aimed at long‑term use

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...

Eli Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Pfizer signs license deal with Fosun unit for obesity drug

Pfizer Inc. has entered into an exclusive global collaboration and licensing deal with a unit of Shanghai Fosun ...
MarketWatch

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Pfizer Inc. pulled off a comeback win, beating out Danish drug giant Novo Nordisk to acquire obesity drug developer Metsera Inc. in a deal that values the biotechnology company at up to $9.1 billion.

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity ...